Latest News & Features
Big Pharma
The US Court of Appeals for the Federal Circuit has agreed to reconsider its precedential ruling against Teva Pharmaceuticals for producing a generic hypertension and heart failure treatment, according to a Bloomberg Law report. 10 February 2021
Americas
The US Court of Appeals for the Federal Circuit has upheld a decision by a district court that an inventor cannot further extend his shoulder surgery patent after already being granted a term adjustment period by the US Patent and Trademark Office. 9 February 2021
Americas
Johnson & Johnson has settled its case against Advanced Inventory Management, trading as eSutures, which it accused of distributing counterfeit and contaminated surgical tools. 9 February 2021
Europe
Under close scrutiny by regulators, the rules around second medical use patents vary from country to country, explains Jackie Mulryne of Arnold & Porter. 8 February 2021
Biotechnology
Pfizer has struck a research and licensing agreement with Belgium biopharmaceutical company Imcyse to develop treatments for rheumatoid arthritis using Imotopes - Imcyse’s platform of immunotherapeutics based on synthetic peptides. 5 February 2021
Big Pharma
Jazz Pharmaceuticals has acquired UK medicinal cannabis company GW Pharmaceuticals in a takeover worth $7.2 billion. 4 February 2021
Big Pharma
Chinese drug maker Qilu’s proposed generic version of a cancer treatment infringes three patents, according to a lawsuit filed by Boehringer Ingelheim. 4 February 2021
Big Pharma
Coherus Biosciences has signed a deal with Chinese biopharmaceutical company Shanghai Junshi Biosciences for the development and commercialisation rights to toripalimab, Junshi’s PD-1 inhibitor, in the US and Canada. 4 February 2021
Big Pharma
Russian pharmaceutical company Pharmsynthez has allegedly started producing a generic version of COVID-19 drug remdesivir without the authorisation of the drug’s patent owner, Gilead Sciences. 4 February 2021
Genetics
Biotech company Illumina has won a dispute with Columbia University, after the Court of Appeals for the Federal Circuit backed an earlier ruling that the university’s DNA-sequencing patents were invalid. 2 February 2021